Gene Editing Archives

Vertex and Arbor Strike Deal for Gene-Editing Programs

Beta Thalassemia, Blood Diseases, Business, Cell Therapy, CRISPR/Cas9, Deals, Gene Editing, Partnerships, R&D, Sickle Cell Disease, Type 1 Diabetes

Vertex Pharmaceuticals and Arbor Biotechnologies announced a new collaboration to enhance efforts in developing ex vivo engineered cell therapies, using Arbor’s proprietary CRISPR gene-editing technology for select diseases.

August 24, 2021/by Andrew Humphreys

Gene Editing Company Graphite Bio Launches with $45 Million in Funding

CRISPR/Cas9, Financing, Gene Editing, Gene Sequencing, Gene Therapy, Genetic Sequencing, Health Technology, Series A

Bay Area-based Graphite Bio launched with $45 million in Series A financing and a goal to use gene editing to correct defective genes through high-efficiency site-specific integration of new genetic sequences.

September 16, 2020/by Andrew Humphreys

Celyad’s High Hopes for a Path Forward in Cancer Immunotherapy with CYAD-211

B-cell maturation antigen (BCMA), Biotechnology, CAR-T Therapy, Cell Therapy, Clinical Trials, Gene Editing, Immunotherapies, Metastatic Colorectal Cancer (mCRC), Oncology, R&D, Relapse/Refractory Multiple Myeloma

Celyad Oncology is at the forefront of cutting-edge immunotherapy and is hopeful of providing a new way forward for patients with relapsed/refractory multiple myeloma.

September 2, 2020/by BioSpace

Vertex Pharmaceuticals expands into Duchenne gene therapy with new deals

Acquisitions, Business, Collaborations, Deals, Duchenne Muscular Dystrophy (DMD), Gene Editing, Gene Editing, Genetic neuromuscular diseases, Muscle Wasting Disorders, Myotonic Dystrophy Type 1 (DM1)

Vertex Pharmaceuticals will acquire privately held Exonics Therapeutics for an upfront payment of $245 million and potential milestone payments of up to $750 million.

June 6, 2019/by Reuters Health